AbSci (ABSI) Receives a Buy from H.C. Wainwright
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ramakanth Swayampakula reiterated a Buy rating on AbSci (ABSI) with a $16 price target, citing the company's position in the healthcare sector. This follows a Buy from Truist Financial and contrasts with Morgan Stanley's Hold rating issued in late June.
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on AbSci, with a price target of $16.00.
4th of July Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Ramakanth covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Precigen, and AbSci. According to TipRanks, Ramakanth has an average return of 20.3% and a 48.50% success rate on recommended stocks.
In addition to H.C. Wainwright, AbSci also received a Buy from Truist Financial’s Srikripa Devarakonda in a report issued on July 2. However, on June 25, Morgan Stanley assigned a Hold rating to AbSci (NASDAQ: ABSI).